Backchannelmedia

Backchannelmedia

BURLINGTON, Mass., May 18 /PRNewswire/ -- First Hand Medical today announced the recently completed first round venture investment by Eureka Partners I, LLC to commercialize Carpal Control Therap(TM). The investment is intended in large part to fund a powerful and unique direct to consumer marketing campaign for The Carpal Solution(TM), the first low cost, non-invasive consumer health product that relieves the pain associated with Carpal Tunnel Syndrome (CTS).

The campaign includes a long-form infomercial program featuring compelling personal user experiences, expert medical opinion and a powerful thermal imaging demonstration. An authoritative website has been launched, http://www.MyCarpalTunnel.com, employing state-of-the-art search engine optimization technology for global targeted reach. The website provides a unique information framework empowering the proactive health consumer and the latest encryption technology for secure transactions. Retail discussions with leading pharmacies are underway.

Used by physicians for years, this remarkable therapy is now available directly to consumers under the Carpal Solution brand. As an FDA Class One Device that relieves chronic pain in days, it is particularly well suited for retail pharmacies that like to offer consumers a better first line of defense to common ailments like CTS. Clinically documented, The Carpal Solution is the latest in a new popular class of therapeutic devices that safely treat pain at the source, as opposed to medicinally or through invasive surgery.

CTS is reaching epidemic proportions affecting over 75 million people worldwide. It most often affects people who engage in repetitive hand movements such as office and factory workers, cashiers, mail handlers, etc. The median time lost from work is estimated at 32 days per patient, more than any other cause.(1) It also affects over 20% of pregnant women and has a high incidence among sports enthusiasts.

Developed by a muscular skeletal clinician, The Carpal Solution offers a different approach that is more effective and convenient to use. The therapy is self-applied at night, so it fits easily into an active lifestyle and does not hinder daily hand use. It gently reshapes the connective tissue around the Carpal Tunnel and quickly eliminates hand pain. Sufferers get back to a sound night's sleep and regular activities in days.

Prior to this therapy, conventional treatment options included oral pain medication; restrictive splints that are both uncomfortable, ineffective and result in muscle atrophy; localized steroid injections and invasive surgery in which relapses are common. There are few therapeutic areas where patient dissatisfaction with the conventional treatment is higher. An improved non-invasive therapy is sorely needed.

"Patient compliance is a major issue in medicine. The Carpal Solution is a breakthrough in the treatment of CTS, not only because it offers a better first line of defense to stop progression early, but also because it is so easy for people to self-apply and fits seamlessly into active lifestyles," said Jerome H. Grossman, MD, Director of Healthcare Delivery at Harvard and Chair of Eureka Medical's Expert Advisory Board.

First Hand Medical is a leading supplier of a new class of products focused in sectors where the healthcare system has fallen short of consumer expectations. Products are designed for well informed health consumers who actively seek practical solutions that work. Contact: Donna Voiland at donna@mycarpaltunnel.com, 781-229-5878, http://www.mycarpaltunnel.com

Eureka Partners is a venture firm affiliated with Eureka Medical, the Leading Medical Inventor Network. Eureka Medical evaluates hundreds of medical inventions per year from physician inventors. These devices are screened by an expert medical Advisory Board. The Carpal Solution was selected as the Top Home Health Product http://www.eurekamed.com

(1) Carpal Tunnel Syndrome: Is It Work-Related? Atcheson